TFTelma Francisco

Telma Francisco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Telma Francisco has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of real-world kidney outcomes with predicted outcomes at the time of diagnosis and post-biopsy in a cohort of children with IgA nephropathy

    by Mafalda Félix Cabral, Inês Martins, Miguel Pereira, Gonçalo Vale, Madalena Almeida Borges, Maria Soto-Maior Costa, Fernando Caeiro, Mário Góis, Helena Sousa, Telma Francisco, et al.

    Introduction: IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis, with a variable clinical course. This study aimed to evaluate real-world kidney outcomes in children with IgAN and compare these with predictions from the International IgAN Prediction Tool for children (IIgAN-PT). Methods: A single-center, longitudinal retrospective study was conducted on pediatric patients diagnosed with IgAN from 2010 to 2022. Data on clinical, laboratory, and histological parameters were analyzed. The IIgAN-PT score was calculated for each patient at biopsy and one year after biopsy. The primary outcome was a composite endpoint of ≥30% eGFR decrease or progression to end stage kidney disease (ESKD). Results: Among 23 patients (57% male, median age at biopsy 13.8 years), MEST-C scores showed M1 in 87%, E1 in 22%, S1 in 39%, T1/2 in 13%, and C1 in 26%. During a median 3.1-year follow-up, 26% reached the primary outcome, while the median predicted risk based on IIgAN-PT was 6.5%. Additionally, 57% experienced eGFR decline (annual median decline of 5.6 mL/min/1.73 m2). Application of the updated IIgAN-PT one-year post-biopsy (n = 13) resulted in a median predicted risk of 1.79%, while 23% met the primary outcome. Conclusion: The observed eGFR decline or progression to ESKD was higher than predicted, highlighting the need for early diagnosis, monitoring, and treatment. Small-scale studies like ours underscore the importance of early intervention and may inform the design of larger studies to improve the predictive ability of the IIgAN-PT tool in diverse clinical settings.


  • Open Access

    Comparação de desfechos renais de mundo real com desfechos previstos no momento do diagnóstico e pós-biópsia em uma coorte de crianças com nefropatia por IgA

    by Mafalda Félix Cabral, Inês Martins, Miguel Pereira, Gonçalo Vale, Madalena Almeida Borges, Maria Soto-Maior Costa, Fernando Caeiro, Mário Góis, Helena Sousa, Telma Francisco, et al.

    Resumo Introdução: Nefropatia por IgA (NIgA) é a forma mais comum de glomerulonefrite primária, apresentando curso clínico variável. Este estudo teve como objetivo avaliar desfechos renais de mundo real em crianças com NIgA e compará-los com previsões da International IgAN Prediction Tool (IIgAN-PT) para crianças. Métodos: Realizou-se estudo retrospectivo longitudinal de centro único em pacientes pediátricos diagnosticados com NIgA de 2010-2022. Foram analisados dados sobre parâmetros clínicos, laboratoriais e histológicos. O escore IIgAN-PT foi calculado para cada paciente na biópsia e um ano pós-biópsia. O desfecho primário foi um desfecho composto de redução ≥30% da TFGe ou progressão para doença renal em estágio terminal (DRET). Resultados: Entre 23 pacientes (57% do sexo masculino , idade mediana na biópsia 13,8 anos), os escores MEST-C demonstraram M1 em 87%, E1 em 22%, S1 em 39%, T1/2 em 13% e C1 em 26%. Durante acompanhamento mediano de 3,1 anos, 26% atingiram o desfecho primário, enquanto o risco mediano previsto com base no IIgAN-PT foi 6,5%. Além disso, 57% apresentaram declínio da TFGe (declínio anual mediano de 5,6 mL/min/1,73 m2). A aplicação do IIgAN-PT atualizado um ano pós-biópsia (n = 13) resultou em risco mediano previsto de 1,79%, enquanto 23% atingiram o desfecho primário. Conclusão: O declínio observado da TFGe ou progressão para DRET foi maior que o previsto, destacando a necessidade de diagnóstico, monitoramento e tratamento precoces. Estudos de pequena escala, como o nosso, ressaltam a importância da intervenção precoce e podem orientar o desenho de estudos maiores para aprimorar a capacidade preditiva da ferramenta IIgAN-PT em diversos cenários clínicos.

  • Open Access

    Uma apresentação grave de raquitismo hipocalcêmico dependente de vitamina D associado à hipofosfatemia

    by Gonçalo Vale, Leonor Cardoso, Telma Francisco

    Este é um relato de caso de uma menina de sete anos de idade evacuada de São Tomé e Príncipe devido ao raquitismo. Ela começou a andar aos 3 anos de idade, mas não conseguia mais andar desde os 4 anos e apresentou episódios recorrentes de desconforto respiratório1 1. Maia MLA, Abreu ALS, Nogueira PCK, Val MLDMD, Carvalhaes JTA, Andrade MC. Hypophosphatemic rickets: case report. Rev Paul Pediatr. 2018;36(2):242–7. doi: http://dx.doi.org/10.1590/1984-0462/;2018;36;2;00009. PubMed PMID: 29617471. https://doi.org/10.1590/1984-0462/;2018;... . No exame físico estava desnutrida, apresentava tórax em formato de sino, membros deformados e em varo e falta de dentes. Os exames de sangue revelaram hipocalcemia (6,4 mg/dL) e hipofosfatemia (2,5 mg/dL) graves, fosfatase alcalina (4.161 U/L) e hormônio da paratireoide (509,6 pg/ml) elevados, enquanto os níveis de 25-hidroxivitamina D estavam dentro da faixa normal; a medição de 1,25-di-hidroxivitamina D não foi realizada. O estudo genético identificou mutações em ambas as cópias do gene CYP27B12 2. Kim YM, Jang YY, Jeong JE, Park HJ, Jang JH, Kim JK. A case of vitamin D hydroxylation-deficient rickets type 1A caused by 2 novel pathogenic variants in CYP27B1 gene. Ann Pediatr Endocrinol Metab. 2019;24(2):137–41. doi: http://dx.doi.org/10.6065/apem.2019.24.2.137. PubMed PMID: 31261480. https://doi.org/10.6065/apem.2019.24.2.1... , levando a alterações na função da alfa-1-hidroxilase. Foi feito o diagnóstico de raquitismo dependente de vitamina D tipo 1A.

  • Open Access

    A severe presentation of vitamin D-dependent hypocalcemic rickets associated with hypophosphatemia

    by Gonçalo Vale, Leonor Cardoso, Telma Francisco

    This is a case report of a seven-year-old girl evacuated from Sao Tome and Principe due to rickets. She started walking at age 3, was unable to walk since age 4, and had recurrent episodes of respiratory distress1 1. Maia MLA, Abreu ALS, Nogueira PCK, Val MLDMD, Carvalhaes JTA, Andrade MC. Hypophosphatemic rickets: case report. Rev Paul Pediatr. 2018;36(2):242–7. doi: http://dx.doi.org/10.1590/1984-0462/;2018;36;2;00009. PubMed PMID: 29617471. https://doi.org/10.1590/1984-0462/;2018;... . At physical examination, she was malnourished, had bell-shaped thorax, deformed and varus limbs, and missing teeth. Blood tests revealed severe hypocalcemia (6.4 mg/dL) and hypophosphatemia (2.5 mg/dL), high alkaline phosphatase (4161 U/L) and parathyroid hormone (509.6 pg/ml), normal range 25-hydroxyvitamin D; 1,25-dihydroxyvitamin D was not performed. Genetic study identified mutations in both CYP27B12 2. Kim YM, Jang YY, Jeong JE, Park HJ, Jang JH, Kim JK. A case of vitamin D hydroxylation-deficient rickets type 1A caused by 2 novel pathogenic variants in CYP27B1 gene. Ann Pediatr Endocrinol Metab. 2019;24(2):137–41. doi: http://dx.doi.org/10.6065/apem.2019.24.2.137. PubMed PMID: 31261480. https://doi.org/10.6065/apem.2019.24.2.1... gene copies, leading to alterations in alpha-1-hydroxylase function. A diagnosis of vitamin-D-dependent rickets type 1A was made.

  • Open Access

    Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases: Five-year Experience of a Pediatric Tertiary Hospital in Portugal

    by Mafalda Rebelo, Telma Francisco, Rosário Perry da Câmara, Andreia Pereira, Amets Iraneta, Marta Amorim, Maria João Paiva Lopes, Rita Lopes da Silva, Ana Isabel Cordeiro

    Introduction: Neurocutaneous syndromes (NCS) are a heterogeneous group of conditions with multiorgan involvement and diverse manifestations, evolving throughout life with significant morbidity. A multidisciplinary approach to NCS patients has been advocated, although a specific model is not yet established. The aim of this study was 1) to describe the organization of the recently created Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases (MOCND) at a Portuguese pediatric tertiary hospital; 2) to share our institutional experience focusing on the most common conditions, neurofibromatosis type 1 (NF1) and tuberous sclerosis complex (TSC); 3) to analyze the advantages of a multidisciplinary center and approach in NCS.Methods: Retrospective analysis of 281 patients enrolled in the MOCND over the first five years of activity (October 2016 to December 2021), reviewing genetics, family history, clinical features, complications, and therapeutic strategies for NF1 and TSC.Results: The clinic works weekly with a core team of pediatricians and pediatric neurologists supported by other specialties as needed. Of the 281 patients enrolled, 224 (79.7%) had identifiable syndromes such as NF1 (n = 105), TSC (n = 35), hypomelanosis of Ito (n = 11), Sturge-Weber syndrome (n = 5), and others. In NF1 patients, 41.0% had a positive family history, all manifested café-au-lait macules, 38.1% neurofibromas with 45.0% being large plexiformneurofibromas. Sixteen were under treatment with selumetinib. Genetic testing was performed in 82.9% of TSC patients with pathogenic variants found in TSC2 gene in 72.4% patients (82.7% if considered contiguous gene syndrome). Family history was positive in 31.4%. All TSC patients presented hypomelanotic macules and fulfilled diagnostic criteria. Fourteen patients were being treated with mTOR inhibitors.Conclusion: Offering a systematic and multidisciplinary approach to NCS patients enables timely diagnosis, promotes a structured follow-up, and encourages discussion to outline management plans for optimal care to every patient, with significant impact on the quality of life of patients and families.


  • Primary Hyperoxaluria Type 1: The First Patient Treated with Lumasiran in Portugal

    by Madalena Borges, Hospital Dona Estefânia Pediatric Nephrology Unit, João Martins, Joana Dias, Nuno Fonseca, Telma Francisco, Margarida Abranches

    Primary hyperoxaluria type 1 is a rare genetic disease caused by mutations in AGXT, leading to an excessive hepatic production of oxalate, resulting in urolithiasis, nephrocalcinosis and chronic kidney disease. The authors present the case of a young female with PH1 who is the first patient treated with lumasiran in Portugal, and currently has a follow-up of 18 months.

  • The urine as a diagnostic key for a homozygous EGFR mutation

    by Mafalda Santos, Margarida Almendra, Sofia Bota, Helena Ramos, Telma Francisco

    Primary inherited epidermal growth factor receptor defects have recently been described in severe inflammatory skin disease and diarrhoea case reports. We describe two case reports of female preterm newborns of Roma consanguineous parents who presented both with alopecia and erythroderma/ichthyosis, in addition to nephromegaly at birth in case 1. Later, they both developed hypomagnesaemia and other severe hydroelectrolyte disturbances, recurrent life-threatening sepsis and failure to thrive. Exome sequencing identified a homozygous mutation in the epidermal growth factor receptor, rarely described. Despite optimization of medical supportive care, the prognosis was poor and both patients died before the first year of life. There are few similar cases of epidermal growth factor receptor homozygous mutation reported so far. Our manuscript describes the genetics, clinical presentation, and complex treatment of our two patients, aiming to contribute to new advances in the management of this condition.


  • The Kidney Genetics Clinic: delivering precision medicine for kidney patients

    by Joaquim Calado, Rui Barata, Rita Lucas, Telma Francisco, Rui Gonçalves, Nuno Ribeiro, Fernando Nolasco

    Molecular genetic testing in human traits has traditionally relied on affiliated academic facilities, been focused on specific phenotypes and supported by research funding. We report the experience of the Kidney Genetics Clinic (“consulta de Doenças Renais Hereditárias”) for the past 5 years, a period during which we have outsourced genetic testing. We evaluated the impact of molecular testing in patients’ care, but we also assessed disease‑specific imaging procedures and medicines provided. During the study period, 293 individuals were evaluated. Autosomal Dominant Polycystic Kidney Disease was the most frequent diagnosis (61.8%). In 125 patients, a genetic test was available, and for 76 of these (60.8%) a pathogenic/likely pathogenic variant was identified. Depend‑ ing on the phenotype, the mutation detection rate ranged from 100% (Tuberous Sclerosis Complex) to 15.4% (Autosomal Dominant Tubuloint‑ erstitial Kidney Disease). The impact of genetic testing on patients’ diagnosis and treatments is discussed. Total kidney volume was calculated in 6 patients with Autosomal Dominant Polycystic Kidney Disease and the combined volume for selected angiomyolipoma monitored in 3 individuals with the Tuberous Sclerosis Complex. Currently, 4 patients are being treated with Everolimus/Votubia™, 3 with Eculizumab/Soliris™ and 2 with Tolvaptan/Jinarc™. Our results demonstrate the feasibility of genetic molecular testing in a clinical setting while relying on outsourced sites for gene testing. We emphasize that it was only because the Kidney Genetics Clinic was given the opportunity to look after several patients affected by the same specific orphan or rare diseases (cohort enrichment) that we were able to improve diagnostic skills and deliver personalized medicines.


  • Open Access

    X-linked hypophosphatemic rickets: a new mutation

    by Patrícia Maio, Lia Mano, Sara Rocha, Rute Baeta Baptista, Telma Francisco, Helena Sousa, João Parente Freixo, Margarida Abranches

    Phosphopenic rickets may be caused by mutations in the PHEX gene (phosphate regulating endopeptidase homolog X-linked). Presently, more than 500 mutations in the PHEX gene have been found to cause hypophosphatemic rickets. The authors report a clinical case of a 4-year-old girl with unremarkable family history, who presented with failure to thrive and bowing of the legs. Laboratory tests showed hypophosphatemia, elevated alkaline phosphatase, normal calcium, mildly elevated PTH and normal levels of 25(OH)D and 1.25(OH)D. The radiological study showed bone deformities of the radius and femur. Clinical diagnosis of phosphopenic rickets was made and the genetic study detected a heterozygous likely pathogenic variant of the PHEX gene: c.767_768del (p.Thr256Serfs*7). This variant was not previously described in the literature or databases. Knowledge about new mutations can improve patient’s outcome. Genetic analysis can help to establish a genotype-phenotype correlation.